Mycoplasma Testing Market Size is projected to experience significant growth from 2022 to 2028. The technique is deployed for determining if a person presently has or had recently been through a mycoplasma infection. This group of tests measures antibodies in the blood that have been produced in response to a mycoplasma infection and detects the microorganism directly by means of culturing or with the help of its DNA (generic material) in a body sample.
Based on product, the mycoplasma testing market is expected to record considerable growth from the kits & regents segment through 2028. Numerous market players have come up with a range of products useful in the detection and testing of mycoplasma. These bacterial organisms can be a serious issue for numerous laboratories given that they can contaminate cell cultures, leading to altered phenotypes and a potential impact on cell lines and experimental results. A few common methods of mycoplasma detection include metabolic enzyme activity assays, enzyme-based immunosorbent assays (ELISA), and PCR and qPCR assays.
On the basis of application, the cell line testing segment is estimated to register commendable expansion during 2022-2028. This is because mycoplasma testing kits facilitate the effective and fast identification of mycoplasma-contaminated cell cultures. The technique enables the highly sensitive detection of both, non-cultivable and cultivable mycoplasma species. The contamination of cell lines with mycoplasma is a widespread issue and visible signs such as pH-changes or turbidity are rare.
This has escalated the demand for cell line testing as mycoplasma infections can result in a number of cellular alterations, that range from altered immunological properties and decelerated growth rate to morphologic and metabolic changes.
North America mycoplasma testing market is poised to depict appreciable growth till 2028. This rise is attributed to an increase in the formulation of testing guidelines by several countries including the U.S. Events of mycoplasma contamination can result in altered physio-chemical properties of cells and unsafe biopharmaceuticals. Numerous regulatory agencies across the globe have mandated testing for the presence of mycoplasma contamination in manufacturing and development processes.
Leading companies in the market include Merck, Abbott, Roche Ltd, Charles River Laboratories, Thermo Fisher Scientific, Lonza Group, Eurofins Scientific, Agilent Technologies, PromoCell GmbH, Sartorius AG, and others. These leaders are focusing on the adoption of expansion strategies such as mergers, acquisitions, and the development of various mycoplasma testing methods for consolidating their position in the market.
For instance, in November 2021, the Life Science Group Sartorius rolled out its Sartolab RF/BT 150-1000 vacuum filtration units. Launched for meeting various applications including mycoplasma removal, the product has been redesigned for offering higher capacity and faster filtration with greater physical stability.
The COVID-19 pandemic has propelled the demand for mycoplasma testing services given the identification of mycoplasma pneumoniae in SARS-CoV-2 patients. This is mainly due to the resultant issues of autoimmune activation, cytokine and hemodynamic dysfunction, mitochondrial dysfunction, and other complications that cannot be easily corrected in patients having pre-existing health conditions. As per studies, mycoplasma spp. have been routinely discovered as co-infections in an extensive number of clinical conditions, and in some instances, this has advanced to a fatal disease.
Market, by Product
Market, by Technology
Market, by Application
Market, by End-use
The above information is provided for the following regions and countries: